BACKGROUND:Anti-tumour necrosis factor (TNF) treatment is clinically efficacious in patients with active ankylosing spondylitis (AS) and leads to improvement of spinal inflammation, as assessed by magnetic resonance imaging. It is unclear whether anti-TNF treatment affects chronic spinal changes in AS. OBJECTIVES: To analyse the effect of infliximab on the radiographic course of AS over 2 years. METHODS: Complete sets of lateral radiographs of the cervical spine and lumbar spine were available from 82 patients from two sources: 41 patients (group 1) had been treated withinfliximab (5 mg/kg/6 weeks) as part of a recent randomised controlled trial and 41 patients (group 2) were part of the early German AS cohort (GESPIC), without controlled interventions. Radiographs were obtained at baseline and after 2 years and scored by the modified Stokes AS Spinal Score (mSASSS). RESULTS: Patients in the infliximab group were older, had a longer disease duration, and more radiographic damage at baseline. The mean (SD) mSASSS change was 0.4 (2.7) and 0.7 (2.8) for groups 1 and 2, respectively (p = NS). Radiographic damage at baseline was a predictor for more radiographic progression. Patients with baseline damage who were treated with infliximab showed a trend for less radiographic progression. No correlations between clinical parameters and radiographic progression were found. CONCLUSIONS:Patients with AS treated withinfliximab had less radiographic progression after 2 years. Patients with prevalent radiographic damage are prone to develop more damage over time. Infliximab may decelerate radiographic progression in such patients. Larger studies are needed to prove that anti-TNF treatment inhibits structural damage.
RCT Entities:
BACKGROUND:Anti-tumour necrosis factor (TNF) treatment is clinically efficacious in patients with active ankylosing spondylitis (AS) and leads to improvement of spinal inflammation, as assessed by magnetic resonance imaging. It is unclear whether anti-TNF treatment affects chronic spinal changes in AS. OBJECTIVES: To analyse the effect of infliximab on the radiographic course of AS over 2 years. METHODS: Complete sets of lateral radiographs of the cervical spine and lumbar spine were available from 82 patients from two sources: 41 patients (group 1) had been treated with infliximab (5 mg/kg/6 weeks) as part of a recent randomised controlled trial and 41 patients (group 2) were part of the early German AS cohort (GESPIC), without controlled interventions. Radiographs were obtained at baseline and after 2 years and scored by the modified Stokes AS Spinal Score (mSASSS). RESULTS:Patients in the infliximab group were older, had a longer disease duration, and more radiographic damage at baseline. The mean (SD) mSASSS change was 0.4 (2.7) and 0.7 (2.8) for groups 1 and 2, respectively (p = NS). Radiographic damage at baseline was a predictor for more radiographic progression. Patients with baseline damage who were treated with infliximab showed a trend for less radiographic progression. No correlations between clinical parameters and radiographic progression were found. CONCLUSIONS:Patients with AS treated with infliximab had less radiographic progression after 2 years. Patients with prevalent radiographic damage are prone to develop more damage over time. Infliximab may decelerate radiographic progression in such patients. Larger studies are needed to prove that anti-TNF treatment inhibits structural damage.
Authors: J Braun; X Baraliakos; W Golder; K-G Hermann; J Listing; J Brandt; M Rudwaleit; S Zuehlsdorf; M Bollow; J Sieper; D van der Heijde Journal: Ann Rheum Dis Date: 2004-04-05 Impact factor: 19.103
Authors: J Braun; X Baraliakos; W Golder; J Brandt; M Rudwaleit; J Listing; M Bollow; J Sieper; D Van Der Heijde Journal: Arthritis Rheum Date: 2003-04
Authors: J Braun; X Baraliakos; J Brandt; J Listing; A Zink; R Alten; G Burmester; E Gromnica-Ihle; H Kellner; M Schneider; H Sörensen; H Zeidler; J Sieper Journal: Rheumatology (Oxford) Date: 2005-03-09 Impact factor: 7.580
Authors: Astrid J B Wanders; Robert B M Landewé; Anneke Spoorenberg; Maxime Dougados; Sjef van der Linden; Herman Mielants; Hille van der Tempel; Désirée M F M van der Heijde Journal: Arthritis Rheum Date: 2004-08
Authors: J Braun; J Brandt; J Listing; A Zink; R Alten; G Burmester; W Golder; E Gromnica-Ihle; H Kellner; M Schneider; H Sörensen; H Zeidler; J Reddig; J Sieper Journal: Arthritis Rheum Date: 2003-08
Authors: J Braun; J Zochling; E Märker-Hermann; G Stucki; H Böhm; M Rudwaleit; H Zeidler; J Sieper Journal: Z Rheumatol Date: 2006-12 Impact factor: 1.372
Authors: J Zochling; D van der Heijde; R Burgos-Vargas; E Collantes; J C Davis; B Dijkmans; M Dougados; P Géher; R D Inman; M A Khan; T K Kvien; M Leirisalo-Repo; I Olivieri; K Pavelka; J Sieper; G Stucki; R D Sturrock; S van der Linden; D Wendling; H Böhm; B J van Royen; J Braun Journal: Ann Rheum Dis Date: 2005-08-26 Impact factor: 19.103
Authors: Burkhard F Leeb; Elke Böttcher; Hans-Peter Brezinschek; Christoph Czerwenka; Manfred Herold; Hans Hitzelhammer; Franz Mayrhofer; Rudolf Puchner; Franz Rainer; Bernhard Rintelen; Michael Schirmer; Ulrike Stuby; Hans Bröll Journal: Clin Rheumatol Date: 2009-11-11 Impact factor: 2.980